السويد - السويدية - Läkemedelsverket (Medical Products Agency)

schering ag - testosteronenantat - injektionsvätska, lösning - 250 mg/ml - testosteronenantat 250 mg aktiv substans; bensylbensoat hjälpämne - testosteron

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - testosteronundekanoat - kapsel, mjuk - 40 mg - glycerol hjälpämne; para-orange hjälpämne; testosteronundekanoat 40 mg aktiv substans; propylenglykol hjälpämne

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

medartuum ab - testosteronundekanoat - injektionsvätska, lösning - 1000 mg/4 ml - bensylbensoat hjälpämne; testosteronundekanoat 1000 mg aktiv substans

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

novartis sverige ab - metyrapon - kapsel, mjuk - 250 mg - natriumetylparahydroxibensoat hjälpämne; natriumpropylparahydroxibensoat hjälpämne; glycerol 85% hjälpämne; metyrapon 250 mg aktiv substans - metyrapon

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

octapharma ab - anti-d immunglobulin, humant - injektionsvätska, lösning - 750 ie/ml - anti-d immunglobulin, humant 750 ie aktiv substans

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

as grindeks - oxytocin - injektions-/infusionsvätska, lösning - 16,7 mikrogram/ml - oxytocin 16,7 mikrog aktiv substans - oxytocin

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

as grindeks - oxytocin - injektions-/infusionsvätska, lösning - 8,3 mikrogram/ml - oxytocin 8,3 mikrog aktiv substans - oxytocin

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatiska neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatiska neoplasmer - endokrin terapi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - immunologiska medel för suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. en annan viktig bidragsgivare till vildsvin, skatole, kan också minskas som en indirekt effekt. aggressiva och sexuella (montering) beteenden minskar också. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).